0001140361-24-017377.txt : 20240402
0001140361-24-017377.hdr.sgml : 20240402
20240402210137
ACCESSION NUMBER: 0001140361-24-017377
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240331
FILED AS OF DATE: 20240402
DATE AS OF CHANGE: 20240402
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kestenberg-Messina Kaitlin M.
CENTRAL INDEX KEY: 0002017423
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36728
FILM NUMBER: 24816639
MAIL ADDRESS:
STREET 1: 5800 PARK OF COMMERCE BLVD. NW,
CITY: BOCA RATON
STATE: FL
ZIP: 33487
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ADMA BIOLOGICS, INC.
CENTRAL INDEX KEY: 0001368514
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 562590442
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: C/O ADMA BIOLOGICS, INC.
STREET 2: 465 STATE ROUTE 17
CITY: RAMSEY
STATE: NJ
ZIP: 07446
BUSINESS PHONE: (201) 478-5552
MAIL ADDRESS:
STREET 1: C/O ADMA BIOLOGICS, INC.
STREET 2: 465 STATE ROUTE 17
CITY: RAMSEY
STATE: NJ
ZIP: 07446
FORMER COMPANY:
FORMER CONFORMED NAME: R&R ACQUISITION VI, INC
DATE OF NAME CHANGE: 20060707
4
1
form4.xml
FORM 4
X0508
4
2024-03-31
0001368514
ADMA BIOLOGICS, INC.
ADMA
0002017423
Kestenberg-Messina Kaitlin M.
C/O ADMA BIOLOGICS, INC.
5800 PARK OF COMMERCE BLVD. NW,
BOCA RATON
FL
33487
true
COO and SVP, Compliance
false
Common Stock
2024-03-31
4
F
0
2085
6.6
D
112190
D
Common Stock
2024-04-01
4
A
0
192320
0
A
304510
D
Stock Option (right to buy)
6.54
2024-04-01
4
A
0
300328
0
A
2034-04-01
Common Stock
300328
300328
D
Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (RSUs). This is not an open market sale of securities.
As of the transaction date, represents 112,190 shares of Common Stock acquired pursuant to the vesting of RSUs.
These shares represent RSUs that will vest in four equal installments (25% per installment) on each annual anniversary of the date of grant over four years, in each case under the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan") subject to the reporting person's continued service as of the applicable vesting date.
Includes, as of the transaction date, (i) 192,320 RSUs granted on April 1, 2024 and reported on this Form 4, subject to vesting as set forth in footnote (3); and (ii) 112,190 shares acquired pursuant to the vesting of RSUs.
The option vests over four years with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on the four-year anniversary of the grant date.
/s/ Kaitlin M. Kestenberg-Messina, by Adam S. Grossman as Attorney-in-fact
2024-04-02